The U.S. onychomycosis market (prescription drugs) has increased with a healthy growth rate over the years and is expected to increase further during the forecasted period.
The U.S. onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc.
Key Topics Covered
2. Introduction
3. Global Market Analysis
4. U.S. Market Analysis
5. Competitive Landscape
6. Company Profiles
- Valeant Pharmaceuticals
- Pfizer Inc.
- Novartis AG
- Johnson & Johnson
For more information about this report visit https://www.researchandmarkets.com/research/hcgc2m/the_u_s?w=4
